News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Benzinga Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Scribe Therapeutics (SCTX) director Joshua Bleharski was granted 14,725 stock options with an exercise price of $15.00 per share, expiring on July 22, 2036. The options will vest in three equal annual installments on July 23 of 2027, 2028, and 2029, contingent on his …
Avoro Capital Advisors LLC, Avoro Ventures LLC, and Behzad Aghazadeh have reported a collective beneficial ownership of 16.37% in Scribe Therapeutics, Inc. (SCTX) common stock following the company's IPO. This stake, totaling 3,088,888 shares, arose from the conversion of Series B preferred stock, purchases …
Scribe Therapeutics CEO Benjamin L. Oakes received three option awards for the company's common stock. These include a fully vested grant of 12,969 options on March 13, 2026, and two grants on July 23, 2026: a time-based option for 264,784 shares vesting monthly over …
Scribe Therapeutics CFO David Parrot received significant equity awards, including time-vested and performance-based stock options totaling over 200,000 shares, both priced at $15.00. He also reported indirect open-market purchases of 2,666 common shares for family members at the same price. These transactions follow a …
Scribe Therapeutics (SCTX) ten percent owner Brett Staahl has filed an initial statement of beneficial ownership, reporting 524,336 shares of Common Stock held directly. Additionally, Staahl holds four stock option awards with various exercise prices and expiration dates ranging from 2030 to 2036, covering …
This article provides a brief mention of the free cash flow for Scribe Therapeutics Inc. (NASDAQ: SCTX) as found on TradingView. It appears to be a financial data point without further analysis or details within the snippet provided. The primary content available is navigational …
Behzad Aghazadeh, through funds managed by Avoro, disclosed a 16.37% beneficial stake in Scribe Therapeutics, Inc. (SCTX) via a Schedule 13D filing on July 30, 2026. This stake includes IPO purchases, converted preferred shares, and open-market buys, with Aghazadeh also serving on Scribe's board. …
Scribe Therapeutics Inc. announced the closing of its upsized initial public offering of 9,867,000 shares at $15.00 per share, which included the full exercise of the underwriters' option for additional shares. Concurrently, the company also completed a private placement of 500,000 shares to Sanofi. …
Latham & Watkins LLP advised the underwriters in Scribe Therapeutics Inc.'s upsized initial public offering, which closed at US$155.51 million. The clinical-stage biotechnology company offered 9,867,000 shares at US$15 per share, including the underwriters' full exercise of their option for additional shares. Scribe Therapeutics' …
Scribe Therapeutics, co-founded by Nobel laureate Jennifer Doudna, saw its shares jump 44.3% on its first day of trading. The genetic-medicines company raised $128.7 million in its IPO, selling over 8.5 million shares at $15 each. This successful debut signals a continued rebound for …
Scribe Therapeutics plans to raise $96 million through an IPO to advance its genetic medicine pipeline, including its lead program STX-1150 for lowering cholesterol, with initial data expected in the first half of 2027. The company will allocate significant funds to clinical development of …
Scribe Therapeutics has successfully upsized its IPO, raising $128.7 million to advance its gene-editing pipeline focused on lipid-lowering therapies. The company's lead candidate, STX-1150, targets the PCSK9 gene for cardiovascular disease, with topline data expected in the first half of 2027. Scribe plans to …
ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced the pricing of its upsized …
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Scribe Therapeutics has raised close to $129 millionin the first initial public offering for a developer of gene editing medicines in more …
Search by ticker symbol or company name and select a result to open its chart.